Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sonesitatug Vedotin · AZD0901, CMG-901

Antibody-drug conjugate · Cytotoxic, directed at Claudin-18.2 (CLDN18) · developed by ASTRAZENECA

Phase 2 Most advanced trial

AZN Developer

1 Registered trials

What is Sonesitatug Vedotin?

Sonesitatug vedotin is an antibody-drug conjugate composed of a monoclonal antibody against Claudin-18.2 conjugated to monomethyl auristatin E (MMAE). It binds CLDN18.2 on tumor cells, and upon internalization, MMAE inhibits microtubule polymerization, causing cell cycle arrest and apoptosis. It is studied in gastric and gastroesophageal junction cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD0901, CMG-901
Drug type: Antibody-drug conjugate
Targets: Claudin-18.2 (CLDN18), tubulin (secondary target)
Mechanism: Cytotoxic, directed at Claudin-18.2 (CLDN18)
Pathways: microtubule polymerization, G2/M cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 96ZG83EF42

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07143604	Phase 2	Gastric Cancer	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric CancerGastroesophageal Junction Cancer

Other drugs acting on CLDN18

Osemitamab Phase 1/2 Spevatamig Phase 1/2

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Sonesitatug Vedotin

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z